Related Experiment Video
Updated: Jun 29, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma
Zhenghong Xu1, Lingli Chen, Wangwen Gu
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Abstract:
Human hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted uptake of therapeutic agent in the cell-, tissue- or disease-specific manner represents a potential technology for the treatment of HCC. A new docetaxel-loaded hepatoma-targeted solid lipid nanoparticle (tSLN) was designed and prepared with galactosylated dioleoylphosphatidyl ethanolamine. The cellular cytotoxicity, cellular uptake, subcellular localization, in vivo toxicity, therapeutic effect, biodistribution and histology of tSLNs were investigated. The tSLNs showed the particle size about 120nm with encapsulation efficiency >90%, a low burst effect within the first day and a sustained release for the next 29 days in vitro. Cytotoxicity of tSLNs against hepatocellular carcinoma cell line BEL7402 was superior to Taxotere and non-targeted SLNs (nSLNs). The tSLNs also showed better tolerant and antitumor efficacy in murine model bearing hepatoma compared with Taxotere or nSLNs. The studies on cellular uptake and biodistribution indicated that the better antitumor efficacy of tSLNs was attributed to both the increased accumulation of drug in tumor and more cellular uptake by hepatoma cells. The histology demonstrated that tSLNs had no detrimental effect on both healthy liver and liver with fibrosis. These results implied that this targeted nanocarrier of docetaxel could enhance its antitumor effect in vivo with low systemic toxicity for the treatment of locally advanced and metastatic HCC.
Insights
A novel docetaxel-loaded solid lipid nanoparticle targeted to hepatoma cells demonstrated superior efficacy and safety for treating hepatocellular carcinoma (HCC). This targeted approach enhances drug accumulation in tumors, offering a promising new therapy for advanced HCC.
Area of Science:
- Nanotechnology in Oncology
- Drug Delivery Systems
- Hepatocellular Carcinoma (HCC) Research
Background:
- Hepatocellular carcinoma (HCC) is a leading global cause of cancer mortality.
- Targeted drug delivery systems offer a promising strategy to improve HCC treatment efficacy and reduce systemic toxicity.
- Solid lipid nanoparticles (SLNs) are a viable platform for encapsulating chemotherapeutic agents.
Purpose of the Study:
- To design and evaluate a novel hepatoma-targeted solid lipid nanoparticle (tSLN) loaded with docetaxel for HCC treatment.
- To assess the in vitro and in vivo performance of tSLNs, including cytotoxicity, cellular uptake, drug release, and therapeutic efficacy.
- To investigate the biodistribution and toxicity profile of tSLNs in a murine hepatoma model.
Main Methods:
- Preparation of docetaxel-loaded tSLNs using galactosylated dioleoylphosphatidyl ethanolamine.
- In vitro characterization: particle size, encapsulation efficiency, drug release kinetics, and cytotoxicity assays (BEL7402 cell line).
- In vivo evaluation: antitumor efficacy, biodistribution, and histology in a murine hepatoma model, comparing tSLNs with Taxotere and non-targeted SLNs (nSLNs).
Main Results:
- tSLNs exhibited optimal particle size (~120nm), high encapsulation efficiency (>90%), sustained drug release over 29 days, and low initial burst effect.
- tSLNs demonstrated superior in vitro cytotoxicity against BEL7402 cells compared to Taxotere and nSLNs.
- In vivo studies showed enhanced antitumor efficacy and improved tolerability of tSLNs in a murine hepatoma model, attributed to increased tumor drug accumulation and cellular uptake by hepatoma cells. Histology confirmed no adverse effects on healthy liver or fibrotic liver tissue.
Conclusions:
- The developed docetaxel-loaded tSLNs represent an effective targeted nanocarrier for enhancing antitumor effects in HCC.
- This targeted delivery system shows potential for improving therapeutic outcomes in locally advanced and metastatic HCC while minimizing systemic toxicity.
- The findings support the clinical translation of hepatoma-targeted nanoparticles for improved hepatocellular carcinoma management.
